YahooSeptember 4, 2026 at 8:18 PM NY9 hours ago
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?
Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent completion of zero coupon notes and the additional 2032 convertible announcement come after a surge in momentum, with the share price delivering a 30 day return of 158.73% and a year to date share price return of 371.65%, while the 1 year total shareholder return...
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo
Companies in This Story
Related Stories
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?
Yahoo5 hours ago
Why Atlassian Stock Skyrocketed 92% Higher in August and Why There's Likely More to Come
Yahoo2 hours ago
CEO Brian Niccol Just Announced Incredible News for Starbucks Investors
Yahoo2 hours ago
Here's How Many Shares of Coca-Cola You'd Need for $40,000 in Yearly Dividends
Yahoo2 hours ago
Berkshire Hathaway Outperformed the S&P 500 Over a 60-Year Period Under Warren Buffett. Here's the Stock That Could Help Continue the Streak Under Greg Abel.
Yahoo4 hours ago